LENZ Therapeutics Wins FDA Approval For VIZZ, First Aceclidine Eye Drop For Presbyopia; U.S. Launch Expected October 2025

-25.96%

LENZ Therapeutics, Inc. - Common Stock

LENZ

18.14

-25.96%

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States

First once daily solution to treat blurry near vision with proven efficacy for up to 10 hours

VIZZ samples and product availability in the United States expected as early as October 2025

Conference call and webcast to be held August 1, 2025 at 8:00 a.m. EDT

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), today announced the US Food and Drug Administration ("FDA") approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. Samples are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025. Direct-to-eye care professional sales and marketing activities to be initiated immediately.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.